SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997; 31: 27280
  • 2
    Jacobsen SJ, Guess HA, Panser L et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med 1993; 2: 72935
  • 3
    Berges RR, Pientka L, Höfner K, Senge T, Jonas U. Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol 2001; 39: 6827
  • 4
    Sarma AV, Jacobsen SJ, Girman CJ et al. Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. J Urol 2002; 168: 144652
  • 5
    Roehrborn CG, Boyle P, Bergner D et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999; 54: 6629
  • 6
    Crawford ED, Wilson SS, McConnell JD et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006; 175: 14226
  • 7
    Emberton M, Andriole GL, De La Rosette J et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003; 61: 26773
  • 8
    Kaplan S, Naslund MO. Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey. Int J Clin Pract 2006; 60: 115765
  • 9
    Emberton M, Marberger M, De La Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract 2008; 62: 1826
  • 10
    Roehrborn CG, McConnell JD, Barry MJ et al. AUA Guideline on the management of benign prostatic hyperplasia (BPH) 2003. Updated 2006. Available at: http://www.auanet.org/guidelines/bph.cfm. Accessed May 2007
  • 11
    De La Rosette JJ, Alivizatos G, Madersbacher S et al. EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001; 40: 25663
  • 12
    Watson V, Ryan M, Brown CT, Barnett G, Ellis BW, Emberton M. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2004; 172: 23215
  • 13
    O’Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003; 92: 2626
  • 14
    Bruskewitz R, Girman CJ, Fowler J et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group Proscar Long-Term Efficacy Safety Study. Urology 1999; 54: 6708
  • 15
    McVary KT. Alfuzosin for symptomatic benign prostatic hyperplasia: long- term experience. J Urol 2006; 175: 3542
  • 16
    Rhodes PR, Krogh RH, Bruskewitz RC. Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology 1999; 53: 10908
  • 17
    McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 238798
  • 18
    Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 1998; 160: 135867
  • 19
    Siami P, Roehrborn CG, Barkin J et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart® and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007; 28: 7709
  • 20
    Roehrborn CG, Siami P, Barkin J et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 61621
  • 21
    Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 17704
  • 22
    Chatelain CH, Denis L, Foo JK et al. Recommendations of the International Scientific Committee: evaluation and treatment of lower urinary tract symptoms (LUTS) in older men. In ChatelainC, DenisL, FooKT, KhouryS, McConnellJ eds, Fifth International Consultation on Benign Prostatic Hyperplasia. Health Publications, UK, 2001: 51934
  • 23
    Black L. The psychometric validation of a US English satisfaction measure in patients with benign prostatic hyperplasia. Abstract presented at the 2008 International Society of Pharmacoeconomic and Outcomes Research (ISPOR), Toronto, Canada, May 2008
  • 24
    De La Rosette J, Alivizatos G, Madersbacher S et al. Guidelines on benign prostatic hyperplasia. 2006. Available at: http://www.uroweb.org/fileadmin/user_upload/Guidelines/11%20BPH.pdf. Accessed May 2007
  • 25
    Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 1998; 160: 135867